Mylan's quarterly revenue jumps 31 percent

Markets Reuters

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo (Copyright Reuters 2017)

Generic drugmaker Mylan NV reported a 31.2 percent rise in quarterly revenue, helped by demand for products it gained through the acquisition of Swedish drugmaker Meda last year.

Continue Reading Below

Mylan, under federal investigations related to high prices for its EpiPen emergency allergy treatment, said revenue rose to $3.27 billion in the fourth quarter from $2.49 billion a year earlier.

The company's net profit rose to $417.5 million, or 78 cents per share, in the quarter from $194.6 million, or 38 cents per share, a year earlier.

(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)